Channel Therapeutics to Implement 10-for-1 Reverse Stock Split

MT Newswires Live06-27

Channel Therapeutics (CHRO) said Friday it will implement a 10-for-one reverse split of its common shares.

The reverse stock split is intended to increase the market price of the company's common shares and help it satisfy the initial listing requirements of the NYSE American in connection with the expected closing of the merger between its CHRO Merger Sub unit and Ligand Pharmaceutical's (LGNB) LNHC subsidiary.

The reverse stock split is expected to be effective before markets open on July 1. Once effective, the reverse stock split is expected to reduce the company's issued and outstanding shares to about 648,501 shares from about 6.5 million shares.

Price: 1.47, Change: +0.30, Percent Change: +25.64

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment